Immediate Impact
1 from Science/Nature 58 standout
Citing Papers
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer
2024 Standout
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
2024 Standout
Works of Dana Cullen being referenced
Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8.
2022
LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Dana Cullen | 202 | 137 | 43 | 99 | 14 | 328 | |
| Yulong Wang | 130 | 62 | 54 | 174 | 20 | 272 | |
| Jean-François Fléjou | 98 | 68 | 9 | 83 | 14 | 261 | |
| Cristiano Lanza | 126 | 85 | 8 | 79 | 18 | 275 | |
| Tshela E. Mason | 146 | 93 | 35 | 71 | 20 | 314 | |
| Sushanta K. Banerjee | 50 | 151 | 36 | 202 | 10 | 356 | |
| Paul Chan | 191 | 95 | 9 | 144 | 14 | 335 | |
| SA Watson | 84 | 76 | 27 | 148 | 14 | 263 | |
| Nianyuan Ye | 155 | 92 | 14 | 91 | 13 | 334 | |
| Evangelos Chandanos | 108 | 179 | 18 | 226 | 9 | 358 | |
| Keigo Nishi | 167 | 203 | 12 | 141 | 15 | 368 |
All Works
Loading papers...